CYLD and ovarian cancer: Herein, we will address several key questions: (1) the role of CYLD in regulating DDP resistance in ovarian cancer; (2) the downstream effector(s) of CYLD that mediate DDP resistance in ovarian cancer; (3) the signal pathways that may be associated with CYLD expression and cancer progression; (4) the upstream regulator of CYLD, and (5) whether there are new small molecular inhibitors or drugs that can be used to reverse DDP resistance in CYLD knockdown cells.